Nectero Medical
Dover, US · Founded 2017 · 5 known investors
Find your way into Nectero Medical
74 people in our graph share verified history with the Nectero Medical team — schools, employers, funds. One of them is your warm intro.
Jack Thomas Tomarchiounlockedknows Jack Springer · together at US Army (overlapped)
×10knows the team · via US Army
knows the team · via R3 Vascular
Nectero Therapeutics develops therapeutic devices for vascular medicine, working with key opinion leaders in the field. The company operates in the medical device and biotech space.
Founders & leadership
JS
Jack SpringerinChief Executive OfficerHe serves as executive chairman of R3 Vascular and managing director at RM Global Partners, and previously held the same chairman role at Capture Vascular and served as a board member and consultant to Vatrix Medical. Earlier in his career he was vice president of commercial operations and brand marketing at Medtronic and president of US operations at INVATEC, and he has run JDS Consulting, a medical devices and diagnostics practice.
BR
Bruce RobertsinNamed on SEC filing
Investors · 5
Aphelion Capital
Corewell Health VenturesGrand Rapids
BioStar CapitalreportedCharlevoix · $250K – $3M
Norwest Venture PartnersreportedMenlo Park · $10M – $30M
Also in the syndicate · 1
Boston Scientific Corporationlead
Reported raises · per SEC filings
Form D private placements$51M disclosed across 2 of 3 rounds · 2020–2024
▶$32.8MraisedMay 2024 · 30 investors · BiotechnologyRule 506(b)
▶$32.8MraisedMay 2024 · 30 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Anil DasuDirector
- Colin MorrisonDirector
- Bryan ZieglerExecutive Officer
- Bruce RobertsDirector
- Jack SpringerExecutive Officer, Director
- Robert WhirleyDirector
- Offering amount
- $96.6M
- Amount sold
- $32.8M
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$18.2MraisedSep 2021 · 31 investors · BiotechnologyRule 506(b)
▶$18.2MraisedSep 2021 · 31 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John SpringerExecutive Officer, Director
- Offering amount
- $18.2M
- Amount sold
- $18.2M
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$1.5MofferedApr 2020 · BiotechnologyRule 506(b)
▶$1.5MofferedApr 2020 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John SpringerExecutive Officer, Director
- Bruce RobertsDirector
- Offering amount
- $1.5M
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Nectero Medical do?
- Nectero Therapeutics develops therapeutic devices for vascular medicine, working with key opinion leaders in the field. The company operates in the medical device and biotech space.
- Who are Nectero Medical's investors?
- Nectero Medical's investors include Aphelion Capital, Corewell Health Ventures, BioStar Capital, Norwest Venture Partners.
- How much funding has Nectero Medical raised?
- Nectero Medical has disclosed $51M raised across 2 of its 3 known rounds.
- Where is Nectero Medical headquartered?
- Nectero Medical is headquartered in Dover, US.